Lipolytic and thermogenic depletion of adipose tissue in cancer cachexia

Seminars in Cell and Developmental Biology

Volumn 54, Issue , 2016, Pages 68-81

  Tsoli, Maria ^a   Swarbrick, Michael M ^b   Robertson, Graham R ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Adipose tissue; Brown fat; Cancer cachexia; IL 6; Lipolysis; Thermogenesis

Indexed keywords

ACTIVIN; ALPHA2 GLYCOPROTEIN; INTERLEUKIN 1; INTERLEUKIN 6; MYOSTATIN; PARATHYROID HORMONE RELATED PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ZINC ALPHA2 GLYCOPROTEIN;

APOPTOSIS; BODY COMPOSITION; BODY MASS; BROWN ADIPOSE TISSUE; CACHEXIA; CANCER PATIENT; CIRCADIAN RHYTHM; ENERGY BALANCE; ENERGY EXPENDITURE; ENERGY METABOLISM; ESTERIFICATION; EXPERIMENTAL NEOPLASM; FATTY ACID OXIDATION; FOOD INTAKE; FUNCTIONAL STATUS; HUMAN; INSULIN RESISTANCE; INTRACELLULAR SIGNALING; LIPID TRANSPORT; LIPOGENESIS; LIPOLYSIS; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; REVIEW; SKELETAL MUSCLE; SUBCUTANEOUS FAT; THERMOGENESIS; WEIGHT REDUCTION; WHITE ADIPOSE TISSUE; ADIPOSE TISSUE; ANIMAL; COMPLICATION; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY;

ADIPOSE TISSUE; ANIMALS; CACHEXIA; ENERGY METABOLISM; HUMANS; LIPOLYSIS; NEOPLASMS; THERMOGENESIS;

EID: 84947475334     PISSN: 10849521     EISSN: 10963634     Source Type: Journal    
DOI: 10.1016/j.semcdb.2015.10.039     Document Type: Review

References (161)

1. Dewys W.D., et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients Eastern Cooperative Oncology Group. Am. J. Med. 1980, 69:491-497.
2. Tsoli M., Robertson G. Cancer cachexia: malignant inflammation, tumorkines and metabolic mayhem. Trends Endocrinol. Metab. 2013, 24:174-183.
3. Fearon K., Arends J., Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat. Rev. Clin. Oncol. 2013, 10:90-99.
4. Fearon K.C.H., Glass D.J., Guttridge D.C. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012, 153-166.
5. Ebadi M., Mazurak V.C. Evidence and mechanisms of fat depletion in cancer. Nutrients 2014, 6:5280-5297.
6. Arner P., Langin D. Lipolysis in lipid turnover, cancer cachexia, and obesity-induced insulin resistance. Trends Endocrinol. Metab. 2014, 25:255-262.
7. Blum D., Omlin A., Baracos V.E, Solheim T.S., Tan B.H, et al. Cancer cachexia: a systematic literature review of items and domains associated with involuntary weight loss in cancer. Crit. Rev. Oncol. Hematol. 2011, 80:114-144.
8. Argilés J.M., et al. Consensus on cachexia definitions. J. Am. Med. Dir. Assoc. 2010, 11:229-230.
9. Fearon K.C., et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011, 12:489-495.
10. Martin L., Senesse P., Gioulbasanis I., Antoun S., Bozzetti F., et al. Diagnostic criteria for the classification of cancer-associated weight loss. J. Clin. Oncol. 2015, 33:90-99.
11. Douglas E., McMillan D.C. Towards a simple objective framework for the investigation and treatment of cancer cachexia: the Glasgow Prognostic Score. Cancer Treat. Rev. 2014, 40:685-691.
12. Proctor M.J., Morrison D.S., Talwar D., Balmer S.M., O'Reilly D.S., et al. An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow inflammation outcome study. Br. J. Cancer 2011, 104:726-734.
13. Carson J.A., Baltgalvis K.A. Interleukin 6 as a key regulator of muscle mass during cachexia. Exerc. Sport Sci. Rev. 2010, 38:168-176.
14. Bonetto A., et al. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 in experimental cancer cachexia. Am. J. Physiol. Endocrinol. Metab. 2012, 303:E410-E421.
15. Narsale A.A., Carson J.A. Role of interleukin-6 in cachexia: therapeutic implications. Curr. Opin. Support Palliat. Care 2014, 8:321-327.
16. Petruzelli M., Schweiger M., Schreiber R., Campos-Olivas R., Tsoli M., Swabrick M., et al. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014, 20:433-447.
17. Kir S., White J.P., Kleiner S., Kazak L., Cohen P., et al. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia. Nature 2014, 513:100-104.
18. Balkwill F.R., Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin. Cancer Biol. 2012, 22:33-40.
19. Taniguchi K., Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin. Immunol. 2014, 26:54-74.
20. Middleton K., Jones J., Lwin Z., Coward J.I. Interleukin-6: an angiogenic target in solid tumours. Crit. Rev. Oncol. Hematol. 2014, 89:129-139.
21. Hausman D.B., DiGirolamo M., Bartness T.J., Hausman G.J., Martin R.J. The biology of white adipocyte proliferation. Obes. Rev. 2002, 2:239-254.
22. Reitman M.L., Arioglu E., Gavrilova O., Taylor S.I. Lipoatrophy revisited. Trends Endocrinol. Metab. 2000, 11:410-416.
23. Kraegen E.W., Cooney G.J., Ye M., Thompson A.L., Furler S.M. The role of lipids in the pathogenesis of muscle insulin resistance and beta cell failure in type II diabetes and obesity. Exp. Clin. Endocrinol. Diabetes 2001, 109(Suppl. 2):S189-S201.
24. Zechner R., Zimmermann R., Eichmann T.O., Kohlwein S.D., et al. FAT SIGNALS - lipases and lipolysis in lipid metabolism and signaling. Cell Metab. 2012, 15:279-291.
25. Pagnon J., Matzaris M., Stark R., Meex R.C.R., et al. Identification and characterization of protein kinase A phosphorylation sites in the major lipolytic protein, adipose triglyceride lipase. Endocrinology 2012, 153:4278-4289.
26. Fontana L., Eagon J.C., Trujillo M.E., Scherer P.E., Klein S. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
27. Kammoun H.L., Kraakman M.J., Febbraio M.A. Adipose tissue inflammation in glucose metabolism. Rev. Endocr. Metab. Disord. 2014, 15:31-44.
28. Wunderlich C.M., Hovelmeyer N., Wunderlich F.T. Mechanisms of chronic JAK-STAT3-SOCS3 signaling in obesity. JAK-STAT 2013, 2(2):e23878.
29. Samuel V.T., Shulman G.I. Mechanisms for insulin resistance: common threads and missing links. Cell 2012, 148:852-871.
30. Glass C.K., Olefsky J.M. Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 2012, 15:635-645.
31. Chavez J.A., Summers S.A. A ceramide-centric view of insulin resistance. Cell Metab. 2012, 15:585-594.
32. Fouladiun M., Korner U., Bosaeus I., Daneryd P., et al. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care - correlations with food intake, metabolism, exercise capacity, and hormones. Cancer 2005, 103:2189-2198.
33. Murphy R.A., Wilke M.S., Perrine M., Pawlowicz M., Mourtzakis M., et al. Loss of adipose tissue and plasma phospholipids: relationship to survival in advanced cancer patients. Clin. Nutr. 2010, 29:82-87.
34. Zuijdgeest-van Leeuwen S.D., van den Berg J.W., Wattimena J.L., van der Gaast A., Swart G.R., et al. Lipolysis and lipid oxidation in weight-losing cancer patients and healthy subjects. Metabolism 2000, 49:931-936.
35. Arner P. Differences in lipolysis between human subcutaneous and omental adipose tissues. Ann. Med. 1995, 27:435-438.
36. Michaud A., Boulet M.M., Veilleux A., Noël S., Paris G., Tchernof A. Abdominal subcutaneous and omental adipocyte morphology and its relation to gene expression, lipolysis and adipocytokine levels in women. Metabolism 2014, 63:372-381.
37. Rydén M., et al. Lipolysis - not inflammation, cell death, or lipogenesis - is involved in adipose tissue loss in cancer cachexia. Cancer 2008, 113:1695-1704.
38. Das S.K., Eder S., Schauer S., Diwoky C., Temmel H., et al. Adipose triglyceride lipase contributes to cancer-associated cachexia. Science 2011, 333:233-238.
39. Agustsson T., Rydén M., Hoffstedt J., van Harmelen V., Dicker A., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res. 2007, 67:5531-5537.
40. Laurencikiene J., Stenson B.M., Arvidsson Nordström E., Agustsson T., Langin D., et al. Evidence for an important role of CIDEA in human cancer cachexia. Cancer Res. 2008, 68:9247-9254.
41. Zhou Z., Yon Toh S., Chen Z., Guo K., Ng C.P., Ponniah S. Cidea-deficient mice have lean phenotype and are resistant to obesity. Nat. Genet. 2003, 35:49-56.
42. Abreu-Vieira G., Fischer A.W., Mattsson C., de Jong J.M., Shabalina I.G., Rydén M., et al. Cidea improves the metabolic profile through expansion of adipose tissue. Nat. Commun. 2015, 6:7433.
43. Haugen F., Labori K.J., Noreng H.J., Buanes T., Iversen P.O., Drevon C.A. Altered expression of genes in adipose tissues associated with reduced fat mass in patients with pancreatic cancer. Arch. Physiol. Biochem. 2011, 117:78-87.
44. Dahlman I., Mejhert N., Linder K., Agustsson T., Mutch D.M., et al. Adipose tissue pathways involved in weight loss of cancer cachexia. Br. J. Cancer 2010, 102:1541-1548.
45. Stephens N.A., Skipworth R.J., MacDonald A.J., Greig C.A., et al. Intramyocellular lipid droplets increase with progression of cachexia in cancer patients. J. Cachexia Sarcopenia Muscle 2011, 2:111-117.
46. Chu M.P., Lieffers J., Ghosh S., Belch A.R., Chua N.S., et al. Skeletal muscle radio-density is an independent predictor of response and outcomes in follicular lymphoma treated with chemoimmunotherapy. PLOS ONE 2015, 10:e0127589.
47. Antoun S., Lanoy E., Iacovelli R., Albiges-Sauvin L., Loriot Y., et al. Skeletal muscle density predicts prognosis in patients with metastatic renal cell carcinoma treated with targeted therapies. Cancer 2013, 119:3377-3384.
48. Bosaeus I., Daneryd P., Lundholm K. Dietary intake, resting energy expenditure, weight loss and survival in cancer patients. J. Nutr. 2002, 132(Suppl.):3465S-3466S.
49. Cao D.X., Wu G.H., Zhang B., Quan Y.J., Wei J., et al. Resting energy expenditure and body composition in patients with newly detected cancer. Clin. Nutr. 2010, 29:72-77.
50. Tsoli M., Schweiger M., Vanniasinghe A.S., Painter A., et al. Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLOS ONE 2014, 9:e92966.
51. Tsoli M., Moore M., Burg D., Painter A., Taylor R., et al. Activation of thermogenesis in brown adipose tissue and dysregulated lipid metabolism associated with cancer cachexia in mice. Cancer Res. 2012, 72:4372-4382.
52. Gaudy A.M., Clementi A.H., Campbell J.S., Smrcka A.V., Mooney R.A. Suppressor of cytokine signaling-3 is a glucagon-inducible inhibitor of PKA activity and gluconeogenic gene expression in hepatocytes. J. Biol. Chem. 2010, 285:41356-41365.
53. Kliewer K.L., Ke J.Y., Tian M., Cole R.M., Andridge R.R., Belury M.A. Adipose tissue lipolysis and energy metabolism in early cancer cachexia in mice. Cancer Biol. Ther. 2015, 16:886-897.
54. Bing C., et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br. J. Cancer 2006, 95:1028-1037.
55. Batista M.L., Neves R.X., Peres S.B., Yamashita A.S., et al. Heterogenous time-dependent response of adipose tissue during the development of cancer cachexia. J. Endocrinol. 2012, 215:363-373.
56. Wu J., Cohen P., Spiegelman B.M. Adaptive thermogenesis in adipocytes: is beige the new brown?. Genes Dev. 2013, 27:234-250.
57. Dempersmier J., Sul H.S. Shades of brown: a model for thermogenic fat. Front Endocrinol. 2015, 6:71.
58. Elattar S., Satyanarayana A. Can brown fat win the battle against the white fat?. J. Cell. Physiol. 2015, 230:2311-2317.
59. Zhang W., Cline M.A., Gilbert E.R. Hypothalamus-adipose tissue cross talk: neuropeptide Y and the regulation of energy metabolism. Nutr. Metab. 2014, 11:27.
60. Peirce V., Carobbio S., Vidal-Puig A. The different shades of fat. Nature 2014, 510:76-83.
61. Cannon B., Houstek J., Nedergaard J. Brown adipose tissue. More than an effector of thermogenesis?. Ann. N. Y. Acad. Sci. 1998, 856:171-187.
62. Cannon B., Nedergaard J. Brown adipose tissue: function and physiological significance. Physiol. Rev. 2004, 84:277-359.
63. Lee P., Linderman J.D., Smith S., Brychta R.J., Wang J., et al. Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab. 2014, 19:302-309.
64. Wu Z., Puigserver P., Andersson U., Zhang C., Adelmant G., et al. Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 1999, 98:115-124.
65. Puigserver P., Wu Z., Park C.W., Graves R., Wright M., Spiegelman B.M. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. Cell 1998, 92:829-839.
66. Uldry M., Yang W., St-Oierre J., Lin J., Seale P., Spiegelman B.M. Complementary action of PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab. 2006, 3:333-341.
67. Seale P., Conroe H.M., Estall J., Kajimura S., Frontini A., et al. PRDM16 determines the thermogenic program in subcutaneous white adipose tissue in mice. J. Clin. Invest. 2011, 121:96-105.
68. Rosenwald M., Perdikari A., Rulicke T., Wolfrum C. Bi-directional interconversion of brite and white adipocytes. Nat. Cell Biol. 2013, 15:659-667.
69. Klingenspor M. Cold-induced recruitment of brown adipose tissue thermogenesis. Exp. Physiol. 2003, 88:141-148.
70. Lidell M.E., Seifert E.L., Westergren R., Heglind M., Gowing A., et al. The adipocyte-expressed forkhead transcription factor Foxc2 regulates metabolism through altered mitochondrial function. Diabetes 2011, 60:427-435.
71. Tseng Y.H., Kokkotou E., Schulz T.J., Huang T.L., Winnay J.N., et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. Nature 2008, 454:1000-1004.
72. Hondares E., Iglesias R., Giralt A., et al. Thermogenic activation induces FGF21 expression and release in brown adipose tissue. J. Biol. Chem. 2011, 286:12983-12990.
73. Fisher F.M., Kleiner S., Douris N., Fox E.C., Mepani R.J., et al. FGF21 regulates PGC-1α and browning of white adipose tissues in adaptive thermogenesis. Genes Dev. 2012, 26:271-281.
74. Zhang Y., Li R., Meng Y., Li S., Donelan W., et al. Irisin stimulates browning of white adipocytes through mitogen activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes 2014, 63:514-525.
75. Vegiopoulos A., Müller-Decker K., Strzoda D., Schmitt I., Chichelnitskiy E., et al. Cyclooxygenase-2 controls energy homeostasis in mice by de novo recruitment of brown adipocytes. Science 2010, 328:1158-1161.
76. Cohade C., Mourtzikos K.A., Wahl R.L. USA-Fat: prevalence is related to ambient outdoor temperature-evaluation with 18-FDG PET/CT. J. Nucl. Med. 2003, 44:1267-1270.
77. Cypess A.M., Lehman S., Williams G., Tal I., Rodman D., et al. Identification and importance of brown adipose tissue in adult humans. N. Engl. J. Med. 2009, 360:1509-1517.
78. van Marken Lichtenbelt W.D., Vanhommerig J.W., Smulders N.M., Drossaerts J.M., Kemerink G.J., et al. Cold-activated brown adipose tissue in healthy men. N. Engl. J. Med. 2009, 360:1500-1508.
79. Virtanen K.A., Lidell M.E., Orava J., Heglind M., Westergren R., Niemi T., et al. Functional brown adipose tissue in healthy adults. N. Engl. J. Med. 2009, 360:1518-1525.
80. Lee P., Greenfield J.R., Ho K.K., Fulham M.J. A critical appraisal of the prevalence and metabolic significance of brown adipose tissue in adult humans. Am. J. Physiol 2010, 299:E601-E606.
81. 15O PET measurement of blood flow and oxygen consumption in cold-activated human brown fat. J. Nucl. Med 2013, 54:523-531.
82. Nedergaard J., Cannon B. The changed metabolic world of human brown adipose tissue: therapeutic visions. Cell Metab. 2010, 11:268-272.
83. Jespersen N.Z., Larsen T.J., Peijs L., Daugaard S., Homøe P., et al. A classical brown adipose tissue mRNA signature partly overlaps with brite in the supraclavicular region of adult humans. Cell Metab. 2013, 17:798-805.
84. Christen T., Sheikine Y., Rocha V.Z., Hurwitz S., Goldfine A.B., et al. Increased glucose uptake in visceral versus subcutaneous adipose tissue revealed by PET imaging. JACC Cardiovasc. Imaging 2010, 3:843-851.
85. Ng J.M., Azuma K., Kelley C., Pencek R., Radikova Z., et al. PET imaging reveals distinctive roles for different regional adipose tissue depots in systemic glucose metabolism in nonobese humans. Am. J. Physiol. 2012, 303. E1134-E114.
86. Arruda A.P., Milanski M., Romanato T., Solon C., Coope C., et al. Hypothalamic actions of tumor necrosis factor alpha provide the thermogenic core for the wastage syndrome in cachexia. Endocrinology 2010, 151:683-694.
87. Li G., Klein R.L., Matheny M., King M.A., Meyer E.M., Scarpace P.J. Induction of uncoupling protein 1 by central IL-6 gene delivery is dependent on sympathetic innervation of brown adipose tissue and underlies one mechanism of body weight reduction in rats. Neuroscience 2002, 115:879-889.
88. Torelli G.F., Meguid M.M., Moldawer L.L., Edwards C.K., Kim H.J., et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am. J. Physiol. 1999, 277:R850-R855.
89. Laviano A., Gleason J.R., Meguid M.M., Yang Z.J., Cangiano C., Rossi-Fanelli F. Effects of intra-VMN mianserin and IL-1ra on meal number in anorectic tumor-bearing rats. J. Invest. Med. 2000, 48:40-48.
90. Huang W., Ramsey K.M., Marcheva B., Bass J. Circadian rhythms, sleep, and metabolism. J. Clin. Invest. 2011, 121:2133-2141.
91. Nilsberth C., Elander L., Hamzic N., Norell M., Lonn J., et al. The role of interleukin-6 in lipopolysaccharide-induced fever by mechanisms independent of prostaglandin E2. Endocrinology 2009, 150:1850-1860.
92. Russell S.T., Zimmerman T.P., Domin B.A., Tisdale M.J. Induction of lipolysis in vitro and loss of body fat in vivo by zinc-alpha2-glycoprotein. Biochim. Biophys. Acta 2004, 1636:59-68.
93. Bing C., Bao Y., Jenkins J., Sanders P., Manieri M., et al. Zinc-alpha2-glycoprotein, a lipid mobilizing factor, is expressed in adipocytes and is up-regulated in mice with cancer cachexia. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:2500-2505.
94. Rydén M., Agustsson T., Andersson J., Bolinder J., Toft E., Arner P. Adipose zinc-α2-glycoprotein is a catabolic marker in cancer and noncancerous states. J. Intern. Med. 2012, 271:414-420.
95. Roca-Rodríguez M.M., El Bekay R., Garrido-Sanchez L., Gómez-Serrano M., Coin-Aragüez L., et al. Parathyroid hormone-related protein, human adipose-derived stem cells adipogenic capacity and healthy obesity. J. Clin. Endocrinol. Metab. 2015, 100:E826-E835.
96. Vilardaga J.P., Romero G., Friedman P.A., Gardella T.J. Molecular basis of parathyroid hormone receptor signaling and trafficking: a family B GPCR paradigm. Cell. Mol. Life Sci. 2011, 68:1-13.
97. Cohade C. Altered biodistribution on FDG-PET with emphasis on brown fat and insulin effect. Sem. Nucl. Med. 2010, 40:283-293.
98. Lee Y.H., Petkova A.P., Mottillo E.P., Granneman J.G. In vivo identification of bipotential adipocyte progenitors recruited by β3-adrenoceptor activation and high-fat feeding. Cell Metab. 2012, 15:480-491.
99. Bianchi A., Bruce J., Cooper A.L., Childs C., Kohli M., et al. Increased brown adipose tissue activity in children with malignant disease. Horm. Metab. Res. 1989, 21:640-641.
100. Chalfant J.S., Smith M.L., Hu H.H., Dorey F.J., Goodarzian F., et al. Inverse association between brown adipose tissue activation and white adipose tissue accumulation in successfully treated pediatric malignancy. Am. J. Clin. Nutr. 2012, 95:1144-1149.
101. Bartelt A., Bruns O.T., Reimer R., Hohenberg H., Ittrich H., Peldschus K., et al. Brown adipose tissue activity controls triglyceride clearance. Nat. Med. 2011, 17:200-205.
102. Ouellet V., Labbé S.M., Blondin D.P., Phoenix S., Guérin B., Haman F., et al. Brown adipose tissue oxidative metabolism contributes to energy expenditure during acute cold exposure in humans. J. Clin. Invest. 2012, 122:545-552.
103. Falconer J.S., Fearon K.C., Plester C.E., Ross J.A., Carter D.C. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann. Surg. 1994, 219:325-331.
104. Simons J.P., Schols A.M., Buurman W.A., Wouters E.F. Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acute-phase response, resting energy expenditure, and catabolic and anabolic hormones. Clin. Sci. 1999, 97:215-222.
105. Sharma R., Cunningham D., Smith P., Robertson G., Dent O., Clarke S.J. Inflammatory (B) symptoms are independent predictors of myelosuppression from chemotherapy in non-Hodgkin lymphoma (NHL) patients - analysis of data from a British National Lymphoma Investigation phase III trial comparing CHOP to PMitCEBO. BMC Cancer 2009, 9:153.
106. Bonetto A., Aydogdu T., Kunzevitzky N., Guttridge D.C., Khuri S., Koniaris L.G., Zimmers T.A. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS ONE 2011, 6:e22538.
107. Grotzinger J., Kurapkat G., Wollmer A., Kalai M., Rose-John S. The family of the IL-6-type cytokines: specificity and promiscuity of the receptor complexes. Proteins 1997, 27:96-109.
108. Hirano T., Kishimoto T. Interleukin-6: possible implications in human diseases. Ric. Clin. Lab. 1989, 19:1-10.
109. Jones S.A., Scheller J., Rose-John S. Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J. Clin. Invest. 2011, 121:3375-3383.
110. Wunderlich C.M., Delic D., Behnke K., Meryk A., Strohle P., Chaurasia B., et al. Cutting edge: inhibition of IL-6 trans-signaling protects from malaria-induced lethality in mice. J. Immunol. 2012, 188:4141-4144.
111. Kraakman M.J., Kammoun H.L., Allen T.L., Deswaerte V., Henstridge D.C., Estevez E., et al. Blocking IL-6 trans-signaling prevents high-fat diet-induced adipose tissue macrophage recruitment but does not improve insulin resistance. Cell Metab. 2015, 21:403-416.
112. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1993, 259:87-91.
113. Yudkin J.S., Stehouwer C.D., Emeis J.J., Coppack S.W. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler. Thromb. Vasc. Biol. 1999, 19:972-978.
114. Vozarova B., Weyer C., Hanson K., Tataranni P.A., Bogardus C., Pratley R.E. Circulating interleukin-6 in relation to adiposity, insulin action, and insulin secretion. Obes. Res. 2001, 9:414-417.
115. Vgontzas A.N., Papanicolaou D.A., Bixler E.O., Kales A., Tyson K., Chrousos G.P. Elevation of plasma cytokines in disorders of excessive daytime sleepiness: role of sleep disturbance and obesity. J. Clin. Endocrinol. Metab. 1997, 82:1313-1316.
116. Bastard J.P., Jardel C., Bruckert E., Blondy P., Capeau J., Laville M., et al. Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss. J. Clin. Endocrinol. Metab. 2000, 85:3338-3342.
117. Swarbrick M.M., Stanhope K.L., Austrheim-Smith I.T., Van Loan M.D., Ali M.R., Wolfe B.M., et al. Longitudinal changes in pancreatic and adipocyte hormones following Roux-en-Y gastric bypass surgery. Diabetologia 2008, 51:1901-1911.
118. Yudkin J.S., Kumari M., Humphries S.E., Mohamed-Ali V. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link?. Atherosclerosis 2000, 148:209-214.
119. Senn J.J., Klover P.J., Nowak I.A., Mooney R.A. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 2002, 51:3391-3399.
120. Kim H.J., Higashimori T., Park S.Y., Choi H., Dong J., Kim Y.J., et al. Differential effects of interleukin-6 and -10 on skeletal muscle and liver insulin action in vivo. Diabetes 2004, 53:1060-1067.
121. Wallenius V., Wallenius K., Ahren B., Rudling M., Carlsten H., Dickson S.L., et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat. Med. 2002, 8:75-79.
122. Matthews V.B., Allen T.L., Risis S., Chan M.H., Henstridge D.C., Watson N., et al. Interleukin-6-deficient mice develop hepatic inflammation and systemic insulin resistance. Diabetologia 2010, 53:2431-2441.
123. Sadagurski M., Norquay L., Farhang J., D'Aquino K., Copps K., White M.F. Human IL6 enhances leptin action in mice. Diabetologia 2010, 53:525-535.
124. Mukumoto H., Takahashi Y., Ando M., Nishikawa M., Takakura Y. Expression profile-dependent improvement of insulin sensitivity by gene delivery of interleukin-6 in a mouse model of type II diabetes. Mol. Pharm. 2013, 10:3812-3821.
125. Ma Y., Gao M., Sun H., Liu D. Interleukin-6 gene transfer reverses body weight gain and fatty liver in obese mice. Biochim. Biophys. Acta 2015, 1852:1001-1011.
126. De Benedetti F., Meazza C., Martini A. Role of interleukin-6 in growth failure: an animal model. Horm. Res. 2002, 58(Suppl. 1):24-27.
127. Wunderlich F.T., Strohle P., Konner A.C., Gruber S., Tovar S., Bronneke H.S., et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 2010, 12:237-249.
128. Cressman D.E., Greenbaum L.E., DeAngelis R.A., Ciliberto G., Furth E.E., Poli V., et al. Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 1996, 274:1379-1383.
129. Hong F., Radaeva S., Pan H.N., Tian Z., Veech R., Gao B. Interleukin 6 alleviates hepatic steatosis and ischemia/reperfusion injury in mice with fatty liver disease. Hepatology 2004, 40:933-941.
130. Pedersen B.K., Febbraio M.A. Muscle as an endocrine organ: focus on muscle-derived interleukin-6. Physiol. Rev. 2008, 88:1379-1406.
131. Pedersen B.K., Febbraio M.A. Muscles, exercise and obesity: skeletal muscle as a secretory organ. Nat. Rev. Endocrinol. 2012, 8:457-465.
132. Steensberg A., van Hall G., Osada T., Sacchetti M., Saltin B., Pedersen B.K. Production of interleukin-6 in contracting human skeletal muscles can account for the exercise-induced increase in plasma interleukin-6. J. Physiol. 2000, 529(Pt 1):237-242.
133. Keller C., Steensberg A., Pilegaard H., Osada T., Saltin B., Pedersen B.K., et al. Transcriptional activation of the IL-6 gene in human contracting skeletal muscle: influence of muscle glycogen content. FASEB J. 2001, 15:2748-2750.
134. Hiscock N., Chan M.H., Bisucci T., Darby I.A., Febbraio M.A. Skeletal myocytes are a source of interleukin-6 mRNA expression and protein release during contraction: evidence of fiber type specificity. FASEB J. 2004, 18:992-994.
135. Ullum H., Haahr P.M., Diamant M., Palmo J., Halkjaer-Kristensen J., Pedersen B.K. Bicycle exercise enhances plasma IL-6 but does not change IL-1 alpha, IL-1 beta IL-6, or TNF-alpha pre-mRNA in BMNC. J. Appl. Physiol. (1985) 1994, 77:93-97.
136. Moldoveanu A.I., Shephard R.J., Shek P.N. Exercise elevates plasma levels but not gene expression of IL-1beta IL-6, and TNF-alpha in blood mononuclear cells. J. Appl. Physiol. (1985) 2000, 89:1499-1504.
137. Fischer C.P. Interleukin-6 in acute exercise and training: what is the biological relevance?. Exerc. Immunol. Rev. 2006, 12:6-33.
138. Fäldt J., Wernstedt I., Fitzgerald S.M., Wallenius K., Bergström G., Jansson J.O. Reduced exercise endurance in interleukin-6-deficient mice. Endocrinology 2004, 145:2680-2686.
139. Xu H., Barnes G.T., Yang Q., Tan G., Yang D., Chou C.J., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J. Clin. Invest. 2003, 112:1821-1830.
140. Weisberg S.P., McCann D., Desai M., Rosenbaum M., Leibel R.L., Ferrante A.W. Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 2003, 112:1796-1808.
141. Mathis D. Immunological goings-on in visceral adipose tissue. Cell Metab. 2013, 17:851-859.
142. Fried S.K., Bunkin D.A., Greenberg A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab. 1998, 83:847-850.
143. Kern P.A., Ranganathan S., Li C., Wood L., Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol. Endocrinol. Metab. 2001, 280:E745-E751.
144. Mohamed-Ali V., Goodrick S., Rawesh A., Katz D.R., Miles J.M., Yudkin J.S., et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J. Clin. Endocrinol. Metab. 1997, 82:4196-4200.
145. Crichton M.B., Nichols J.E., Zhao Y., Bulun S.E., Simpson E.R. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells. Mol. Cell. Endocrinol. 1996, 118:215-220.
146. Fain J.N., Madan A.K., Hiler M.L., Cheema P., Bahouth S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2009, 145:2273-2282.
147. Fonseca J.E., Santos M.J., Canhao H., Choy E. Interleukin-6 as a key player in systemic inflammation and joint destruction. Autoimmun. Rev. 2009, 8:538-542.
148. Path G., Bornstein S.R., Gurniak M., Chrousos G.P., Scherbaum W.A., Hauner H. Human breast adipocytes express interleukin-6 (IL-6) and its receptor system: increased IL-6 production by beta-adrenergic activation and effects of IL-6 on adipocyte function. J. Clin. Endocrinol. Metab. 2001, 86:2281-2288.
149. Tchivileva I.E., Tan K.S., Gambarian M., Nackley A.G., Medvedev A.V., Romanov S., et al. Signaling pathways mediating beta3-adrenergic receptor-induced production of interleukin-6 in adipocytes. Mol. Immunol. 2009, 46:2256-2266.
150. Wueest S., Item F., Boyle C.N., Jirkof P., Cesarovic N., Ellingsgaard H., et al. Interleukin-6 contributes to early fasting-induced free fatty acid mobilization in mice. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2014, 306:R861-R867.
151. Petersen E.W., Carey A.L., Sacchetti M., Steinberg G.R., Macaulay S.L., Febbraio M.A., Pedersen B.K. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am. J. Physiol. Endocrinol. Metab. 2005, 288:E155-E162.
152. van Hall G., Steensberg A., Sacchetti M., Fischer C., Keller C., Schjerling P., et al. Interleukin-6 stimulates lipolysis and fat oxidation in humans. J. Clin. Endocrinol. Metab. 2003, 88:3005-3010.
153. Lyngsø D., Simonsen L., Bülow J. Metabolic effects of interleukin-6 in human splanchnic and adipose tissue. J. Physiol. 2002, 543:379-386.
154. Kissebah A.H., Krakower G.R. Regional adiposity and morbidity. Physiol. Rev. 1994, 74:761-811.
155. Manolopoulos K.N., Karpe F., Frayn K.N. Gluteofemoral body fat as a determinant of metabolic health. Int. J. Obes. (Lond.) 2010, 34:949-959.
156. Pinnick K.E., Nicholson G., Manolopoulos K.N., McQuaid S.E., Valet P., Frayn K.N., et al. Distinct developmental profile of lower-body adipose tissue defines resistance against obesity-associated metabolic complications. Diabetes 2014, 63:3785-3797.
157. Burysek L., Houstek J. beta-Adrenergic stimulation of interleukin-1alpha and interleukin-6 expression in mouse brown adipocytes. FEBS Lett. 1997, 411:83-86.
158. Knudsen J.G., Murholm M., Carey A.L., Biensø R.S., Basse A.L., Allen T.L., et al. Role of IL-6 in exercise training- and cold-induced UCP1 expression in subcutaneous white adipose tissue. PLOS ONE 2014, 9:e84910.
159. Stanford K.I., Middelbeek R.J., Townsend K.L., An D., Nygaard E.B., Hitchcox K.M., et al. Brown adipose tissue regulates glucose homeostasis and insulin sensitivity. J. Clin. Invest. 2013, 123:215-223.
160. Hocking S.L., Stewart R.L., Brandon A.E., Suryana E., Stuart E., Baldwin E.M., et al. Subcutaneous fat transplantation alleviates diet-induced glucose intolerance and inflammation in mice. Diabetologia 2015, 58:1587-1600.
161. Ellingsgaard H., et al. Interleukin-6 enhances insulin secretion by increasing glucagon-like peptide-1 secretion from L cells and alpha cells. Nat. Med. 2011, 17:1481-1489.